Clinical trials sponsored by Intergroupe Francophone de Cancerologie Thoracique

Phase breakdown

Conditions studied

Recruiting trials led by Intergroupe Francophone de Cancerologie Thoracique

• A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
  NCT06053099 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
  NCT06656598 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
  NCT05255302 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 44 locations
• Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
  NCT06840834 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)
  NCT06937905 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 40 locations
• Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
  NCT06908993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 29 locations
• Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma
  NCT07234058 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 37 locations

Common questions

How many trials is Intergroupe Francophone de Cancerologie Thoracique recruiting for?

Intergroupe Francophone de Cancerologie Thoracique is the lead sponsor of 7 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.